Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00622193 · ClinicalTrials.gov registry record · Phase 2
Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer
A Phase 2 study, sponsored by Helsinn Therapeutics (U.S.).
- Completed
- Registry status
- Phase 2
- Development phase
- 228
- Enrollment target
NCT00622193 is a Phase 2 study that has completed, run by Helsinn Therapeutics (U.S.). The registered enrollment target is 228 participants.
The verdict
NCT00622193, a Phase 2 study, has completed, sponsored by Helsinn Therapeutics (U.S.).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 228 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate doses of anamorelin for safety and efficacy in patients with non-small cell lung cancer.
Interventions
- DRUG placebo
- DRUG anamorelin HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2008-03 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00622193
The ClinicalTrials.gov registry entry for NCT00622193 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 228 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Helsinn Therapeutics (U.S.), which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00622193 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00622193 about?
NCT00622193 is a clinical study titled "Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer". The purpose of this study is to evaluate doses of anamorelin for safety and efficacy in patients with non-small cell lung cancer.
What is the current status of trial NCT00622193?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 228 participants. The study started on 2008-03. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00622193?
The interventions under investigation include: placebo (DRUG), anamorelin HCl (DRUG).
Who is sponsoring clinical trial NCT00622193?
This trial is sponsored by Helsinn Therapeutics (U.S.), which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.